» Articles » PMID: 29547524

Endogenous Selenoprotein P, a Liver-Derived Secretory Protein, Mediates Myocardial Ischemia/Reperfusion Injury in Mice

Abstract

Selenoprotein P (SeP), a liver-derived secretory protein, functions as a selenium supply protein in the body. SeP has been reported to be associated with insulin resistance in humans through serial analysis of gene expression. Recently, SeP has been found to inhibit vascular endothelial growth factor-stimulated cell proliferation in human umbilical vein endothelial cells, and impair angiogenesis in a mouse hind limb model. In this study, the role of SeP in ischemia/reperfusion (I/R) injury has been investigated. SeP knockout (KO) and littermate wild-type (WT) mice were subjected to 30 min of myocardial ischemia followed by 24 h of reperfusion. The myocardial infarct area/area at risk (IA/AAR), evaluated using Evans blue (EB) and 2,3,5-triphenyltetrazolium chloride (TTC) staining, was significantly smaller in SeP KO mice than in WT mice. The number of terminal de-oxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive nuclei was significantly lower in SeP KO mice than in WT mice. In addition, caspase-3 activation was reduced in SeP KO mice compared to that in WT mice. Furthermore, phosphoinositide 3-kinase/Akt and Erk levels were examined for the reperfusion injury salvage kinase (RISK) pathway. Interestingly, SeP KO significantly increased the phosphorylation of IGF-1, Akt, and Erk compared to that in WT mice after I/R. Finally, I/R-induced myocardial IA/AAR was significantly increased in SeP KO mice overexpressing SeP in the liver compared to other SeP KO mice. These results, together, suggest that inhibition of SeP protects the heart from I/R injury through upregulation of the RISK pathway.

Citing Articles

Emerging Evidence Linking the Liver to the Cardiovascular System: Liver-derived Secretory Factors.

Liu X, Shao Y, Han L, Zhang R, Chen J J Clin Transl Hepatol. 2023; 11(5):1246-1255.

PMID: 37577236 PMC: 10412704. DOI: 10.14218/JCTH.2022.00122.


Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines.

Berezin A, Obradovic Z, Berezina T, Boxhammer E, Lichtenauer M, Berezin A Antioxidants (Basel). 2023; 12(2).

PMID: 36830074 PMC: 9951884. DOI: 10.3390/antiox12020516.


Increases in Hepatokine Selenoprotein P Levels Are Associated With Hepatic Hypoperfusion and Predict Adverse Prognosis in Patients With Heart Failure.

Takeishi R, Misaka T, Ichijo Y, Ishibashi S, Matsuda M, Yamadera Y J Am Heart Assoc. 2022; 11(11):e024901.

PMID: 35621211 PMC: 9238692. DOI: 10.1161/JAHA.121.024901.


Effects of eicosapentaenoic acid on serum levels of selenoprotein P and organ-specific insulin sensitivity in humans with dyslipidemia and type 2 diabetes.

Takeshita Y, Teramura C, Kamoshita K, Takayama H, Nakagawa H, Enyama Y J Diabetes Investig. 2021; 13(3):532-542.

PMID: 34670012 PMC: 8902388. DOI: 10.1111/jdi.13699.


The Impact of Selenium Deficiency on Cardiovascular Function.

Shimada B, Alfulaij N, Seale L Int J Mol Sci. 2021; 22(19).

PMID: 34639053 PMC: 8509311. DOI: 10.3390/ijms221910713.


References
1.
Kristiansen S, Lofgren B, Stottrup N, Khatir D, Nielsen-Kudsk J, Nielsen T . Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia. 2004; 47(10):1716-21. DOI: 10.1007/s00125-004-1514-4. View

2.
Weaver W, Simes R, Betriu A, Grines C, Zijlstra F, Garcia E . Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997; 278(23):2093-8. View

3.
Ishikura K, Misu H, Kumazaki M, Takayama H, Matsuzawa-Nagata N, Tajima N . Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells. Diabetologia. 2014; 57(9):1968-76. DOI: 10.1007/s00125-014-3306-9. View

4.
Vega R, Konhilas J, Kelly D, Leinwand L . Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017; 25(5):1012-1026. PMC: 5512429. DOI: 10.1016/j.cmet.2017.04.025. View

5.
Maclellan W, Schneider M . Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997; 81(2):137-44. DOI: 10.1161/01.res.81.2.137. View